Opin vísindi

Fletta eftir höfundi "Guðbjörnsson, Björn"

Fletta eftir höfundi "Guðbjörnsson, Björn"

Röðun: Raða: Niðurstöður:

  • Icon
    Aldarafmæli D-vítamíns 
    Guðbjörnsson, Björn (2022-07-07)
  • Icon
    Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe 
    Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Ørnbjerg, Lykke Midtbøll; Zavada, Jakub; Glintborg, Bente; MacDonald, Alan; Laas, Karin; Nordström, Dan; Guðbjörnsson, Björn; Iannone, Florenzo; Hellmand, Pasoon; Kvien, Tore Kristian; Rodrigues, Ana Maria; Codreanu, Catalin; Rotar, Ziga; Castrejón Fernández, Isabel; Wallman, Johan Karlsson; Vencovsky, Jiri; Loft, Anne Gitte; Heddle, Maureen; Vorobjov, Sigrid; Hokkanen, Anna Mari; Gröndal, Gerður María; Sebastiani, Marco; van de Sande, Marleen; Kristianslund, Eirik Klami; Santos, Maria José; Mogosan, Corina; Tomsic, Matija; Díaz-González, Federico; Di Giuseppe, Daniela; Hetland, Merete Lund (2023-10)
    This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed ...
  • Icon
    Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration 
    Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, Manuel; Sanchez-Piedra, Carlos; Eklund, Kari; Relas, Heikki; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Jones, Gareth T.; Codreanu, Catalin; Ionescu, Ruxandra; Nekvindova, Lucie; Závada, Jakub; Atas, Nuh; Yolbas, Servet; Fagerli, Karen Minde; Michelsen, Brigitte; Rotar, Ziga; Tomšič, Matija; Iannone, Florenzo; Santos, Maria Jose; Avila-Ribeiro, Pedro; Ørnbjerg, Lykke Midtbøll; Østergaard, Mikkel; Jacobsson, Lennart T.H.; Askling, Johan; Nissen, Michael J. (2021-06-03)
    Background Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains ...
  • Icon
    Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis : a collaborative observational study across five Nordic rheumatology registers 
    Delcoigne, Benedicte; Kopp, Tine Iskov; Arkema, Elizabeth V.; Hellgren, Karin; Provan, Sella Aarrestad; Relas, Heikki; Aaltonen, Kalle; Trokovic, Nina; Guðbjörnsson, Björn; Gröndal, Gerður María; Klami Kristianslund, Eirik; Lindhardsen, Jesper; Dreyer, Lene; Askling, Johan (2023-02-28)
    Objective To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psoriatic ...
  • Icon
    Is the risk of infection higher during treatment with secukinumab than with TNF-inhibitors? : An observational study from the Nordic countries 
    Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan K; Provan, Sella A; Nordström, Dan; Hokkanen, Anna-Mari; Österlund, Jenny; Kristianslund, Eirik; Kvien, Tore K; Guðbjörnsson, Björn; Hetland, Merete Lund; Michelsen, Brigitte; Jacobsson, Lennart; Askling, Johan; Lindström, Ulf (2022-06-20)
    OBJECTIVES: The positioning of secukinumab in the treatment of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) is debated, partly due to a limited understanding of the comparative safety of available treatments. We aimed to assess risk ...
  • Icon
    Methotrexate safety and efficacy in combination therapies in patients with early rheumatoid arthritis : a post-hoc analysis of a randomized controlled trial (NORD-STAR) 
    Lend, Kristina; Koopman, Frieda A; Lampa, Jon; Jansen, Gerrit; L, Merete Hetland; Uhlig, Till; Nordström, Dan; Nurmohamed, Michael; Guðbjörnsson, Björn; Rudin, Anna; Østergaard, Mikkel; Heiberg, Marte S; Sokka-Isler, Tuulikki; Hørslev-Petersen, Kim; Haavardsholm, Espen A; Gröndal, Gerður María; Twisk, Jos W R; van Vollenhoven, Ronald (2023-10-17)
    OBJECTIVE: To investigate methotrexate safety and influence of dose on efficacy outcomes in combination with three different biological treatments and with active conventional treatment (ACT) in early rheumatoid arthritis (RA). METHODS: This post-hoc ...
  • Icon
    A patients’ perspective towards the injection devices for Humira® and Imraldi® in a Nationwide witching program 
    Karlsdóttir, Kristín; Gunnarsdóttir, Anna Ingibjörg; Gröndal, Gerður María; Löve, Þorvarður Jón; Stefánsdóttir, Elínborg; Davíðsdóttir, Lóa Guðrún; Thorleifsdottir, Ragna H.; Guðbjörnsson, Björn (2022-01-27)
    Objective: Due to a tender process in Iceland, all patients on Humira® were switched nationwide to its biosimilar Imraldi® in March 2019. The study aimed to explore the patient's perspective of the Humira® and Imraldi® injection devices. Methods: A ...
  • Icon
    Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial 
    Stockfelt, Marit; Lundell, Anna Carin; Hetland, Merete Lund; Østergaard, Mikkel; Uhlig, Till; Heiberg, Marte Schrumpf; Haavardsholm, Espen A.; Nurmohamed, Michael T.; Lampa, Jon; Nordström, Dan; Petersen, Kim Hørslev; Guðbjörnsson, Björn; Gröndal, Gerður; Aldridge, Jonathan; Andersson, Kerstin; Blennow, Kaj; Zetterberg, Henrik; van Vollenhoven, Ronald; Rudin, Anna (2021-07-13)
    Background: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with clinical characteristics ...
  • Icon
    Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration 
    Ørnbjerg, Lykke Midtbøll; Linde, Louise; Georgiadis, Stylianos; Horskjær Rasmussen, Simon; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K.; Pavelka, Karel; Závada, Jakub; Nissen, Michael J; Jones, Gareth T.; Relas, Heikki; Pirilä, Laura; Tomšič, Matija; Rotar, Ziga; Geirsson, Árni Jón; Guðbjörnsson, Björn; Kristianslund, Eirik K.; van sder Horst-Bruinsma, Irene; Loft, Anne Gitte; Laas, Karin; Iannone, Florenzo; Corrado, Addolorata; Ciurea, Adrian; Santos, Maria José; Santos, Helena; Codreanu, Catalin; Akkoc, Nurullah; Gunduz, Ozgul S.; Glintborg, Bente; Østergaard, Mikkel; Lund Hetland, Merete (2022-10-01)
    Objectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive ...
  • Icon
    Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor : results from 13 European registries 
    Linde, Louise; Ørnbjerg, Lykke M; Georgiadis, Stylianos; Rasmussen, Simon H; Lindström, Ulf; Askling, Johan; Michelsen, Brigitte; Di Giuseppe, Daniela; Wallman, Johan K; Guðbjörnsson, Björn; Löve, Þorvarður Jón; Nordström, Dan C; Yli-Kerttula, Timo; Nekvindová, Lucie; Vencovský, Jiří; Iannone, Florenzo; Cauli, Alberto; Loft, Anne Gitte; Glintborg, Bente; Laas, Karin; Rotar, Ziga; Tomšič, Matija; Macfarlane, Gary J; Möller, Burkhard; van de Sande, Marleen; Codreanu, Catalin; Nissen, Michael J; Birlik, Merih; Erten, Sukran; Santos, Maria J; Vieira-Sousa, Elsa; Hetland, Merete L; Østergaard, Mikkel (2023-06-14)
    OBJECTIVES: In bio-naïve patients with Psoriatic arthritis (PsA) initiating a Tumour Necrosis Factor inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and ...
  • Icon
    Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries 
    Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Guðbjörnsson, Björn; Codreanu, Catalin; Yilmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Möller, Burkhard; Favalli, Ennio G.; Sánchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Löve, Þorvarður Jón; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; van der Horst-Bruinsma, Irene; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Hetland, Merete L. (2022-04-29)
    Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the ...
  • Icon
    Risaæðafrumubólga – sjúkratilfelli með drep í hársverði og skyndiblindu 
    Guðbjörnsson, Björn; Árnadóttir, Berglind; Gröndal, Gerður María; Tryggvason, Þórður (2021-12)
    Sumarið 2020 leitaði kona á níræðisaldri til læknis vegna höfuðverks og sjóntruflana. Greining var óljós og einkenni versnuðu hratt. Hún varð blind á báðum augum og fékk stórt drep í hársvörðinn. Um var að ræða hröð versnandi einkenni risafrumuæðabólgu ...
  • Icon
    Second and third TNF inhibitors in European patients with axial spondyloarthritis : Effectiveness and impact of the reason for switching 
    Linde, Louise; Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Wallman, Johan Karlsson; Di Giuseppe, Daniela; Závada, Jakub; Castrejon, Isabel; Díaz-Gonzalez, Federico; Rotar, Ziga; Tomšič, Matija; Glintborg, Bente; Guðbjörnsson, Björn; Geirsson, Árni Jón; Michelsen, Brigitte; Kristianslund, Eirik Klami; Santos, Maria José; Barcelos, Anabela; Nordström, Dan; Eklund, Kari K; Ciurea, Adrian; Nissen, Michael; Akar, Servet; Hyldstrup, Lise Hejl; Krogh, Niels Steen; Hetland, Merete Lund; Østergaard, Mikkel (2023-09-20)
    OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from ...
  • Icon
    Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network 
    Hellamand, Pasoon; Van De Sande, Marleen; Ørnbjerg, Lykke Midtbøll; Klausch, Thomas; Nurmohamed, Michael T.; Van Vollenhoven, Ronald F.; Nordström, Dan; Hokkanen, Anna Mari; Santos, Maria Jose; Vieira-Sousa, Elsa; Loft, Anne G.; Glintborg, Bente; Hetland, Merete Lund; Lindström, Ulf; Wallman, Johan K.; Michelsen, Brigitte; Klami Kristianslund, Eirik; Ciurea, Adrian; Nissen, Michael S.; Codreanu, Catalin; Mogosan, Corina; Macfarlane, Gary J.; Rotariu, Ovidiu; Rotar, Ziga; Tomšič, Matija; Castrejon, Isabel; Otero-Varela, Lucia; Guðbjörnsson, Björn; Geirsson, Árni Jón; Vencovský, Ji; Pavelka, Karel; Gulle, Semih; Zengin, Berrin; Iannone, Florenzo; Foti, Rosario; Ostergaard, Mikkel; Van Der Horst-Bruinsma, Irene (2023-12-12)
    Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA ...
  • Icon
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : results from four Nordic countries 
    Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella A; Glintborg, Bente; Hetland, Merete Lund; Grøn, Kathrine Lederballe; Peltomaa, Ritva; Relas, Heikki; Turesson, Carl; Guðbjörnsson, Björn; Michelsen, Brigitte; Askling, Johan (2022-03-22)
    OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical ...
  • Icon
    Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis 
    Liu, Jianyang; Idborg, Helena; Korotkova, Marina; Lend, Kristina; van Vollenhoven, Ronald; Lampa, Jon; Rudin, Anna; Nordström, Dan; Guðbjörnsson, Björn; Gröndal, Gerður María; Uhlig, Till; Hørslev-Petersen, Kim; Lund Hetland, Merete; Østergaard, Mikkel; Nurmohamed, Michael; Jakobsson, Per-Johan (2024-03-05)
    BACKGROUND: Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins, ...